Home / Market News / $CAPR
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Analysts Update Ratings and Price Targets for Capricor Therapeutics

Nov 13, 2026, 10:35 PM UTC · Primary ticker $CAPR

This 8-K filing discloses updated analyst ratings and price targets for Capricor Therapeutics. While mostly positive, the varying price targets and one 'hold' rating suggest a mixed but generally optimistic outlook, which could influence investor sentiment and short-term trading activity.

The filing details several financial analysts providing updated coverage on Capricor Therapeutics, with three maintaining 'buy' ratings and one maintaining a 'hold' rating. This information is important for investors as analyst ratings and price targets can influence stock perception and trading decisions. While the majority of ratings are positive, the significant divergence in price targets (from $21 to $54) indicates differing levels of optimism among analysts, which could lead to short-term volatility. The long-term implications depend on whether the company meets or exceeds these expectations, particularly the higher price targets. For traders, the key opportunity lies in understanding the consensus and potential for price movement based on these updated views, while the risk is that the stock may not perform as expected by the more bullish analysts.

$CAPR positive Analyst rating updates
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.